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Abstract
Background: Obese adults struggle to make the changes necessary to achieve even modest weight loss, though a
decrease in weight by as little as 10% can have significant health benefits. Failure to meet weight loss goals may
in part be associated with barriers to obesity treatment. Wide-spread dissemination of evidence-based obesity
treatment faces multiple challenges including cost, access, and implementing the programmatic characteristics on
a large scale.
Aims: The PDA+: A Personal Digital Assistant for Obesity Treatment randomized controlled trial (RCT) was designed
to test whether a PDA-based behavioral intervention enhances the effectiveness of the existing group weight loss
treatment program at VA Medical Centers Managing Overweight/Obese Veterans Everywhere (MOVE!). We also aim
to introduce technology as a way to overcome systemic barriers of traditional obesity treatment.
Methods/Design: Veterans enrolled in the MOVE! group at the Hines Hospital VAMC with BMI ≥ 25 and ≤ 40 and
weigh < 400 pounds, experience chronic pain (≥ 4 on the NRS-I scale for ≥ 6 months prior to enrollment) and are
able to participate in a moderate intensity exercise program will be recruited and screened for eligibility.
Participants will be randomized to receive either: a) MOVE! treatment alone (Standard Care) or b) Standard Care
plus PDA (PDA+). Those randomized to PDA+ will record dietary intake, physical activity, and weight on the PDA.
In addition, they will also record mood and pain intensity, and receive biweekly telephone support for the first 6-
months of the 12-month study. All participants will attend in-person lab sessions every three months to complete
questionnaires and for the collection of anthropomorphic data. Weight loss and decrease in pain level intensity are
the primary outcomes.
Discussion: The PDA+ trial represents an important step in understanding ways to improve the use of technology
in obesity treatment. The trial will address barriers to obesity care by implementing effective behavioral
components of a weight loss intervention and delivering high intensity, low cost obesity treatment. This RCT also
tests an intervention approach supported by handheld technology in a population traditionally considered to have
lower levels of technology literacy.
Trial Registration: ClinicalTrials.gov: NCT00371462
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The obesity epidemic is recognized as an increasingly sig-
nificant U.S. health problem [1]. The percentage of over-
weight (BMI ≥ 25-29.9 kg/m
2)a n do b e s e( B M I≥ 30)
adults has increased in the U.S. from 46% in 1960 to 74%
in 2007-08 [2]. Obesity markedly increases the risk of
cardiovascular disease (CVD), cancer, Type 2 diabetes,
osteoarthritis, gall bladder disease, sleep apnea, respiratory
disease, pain related conditions, and premature mortality
[1,2]. In addition to adverse medical consequences, obesity
takes a toll on quality of life. Among veterans specifically,
BMI in the obese range is significantly associated with pre-
sence of self-reported pain [3]. Weight loss efforts are con-
founded by the comorbid effects of obesity, pain, and the
aforementioned health conditions.
Guidelines recommending lifestyle modifications for all
obese patients, including diet modification and increased
physical activity have been in place for more than
40 years. Yet, fewer than 25% of U.S. adults maintain diet
or physical activity in accord with these recommenda-
tions [4-6]. A decrease in weight by as little as 10% can
have significant health benefits on obesity-related mor-
bidity and mortality [7]. Despite this, few adults can
make the changes necessary to achieve even this amount
of weight loss. It remains unclear to healthcare profes-
sionals what treatment works best to generate achievable
weight loss that is cost-effective and easily disseminated.
Obesity Treatment
There is growing evidence that behavioral treatment and
lifestyle interventions are effective in moderate weight loss
[8]. National Institutes of Health (NIH) guidelines advise
that weight loss and weight maintenance therapy should
be based on a comprehensive weight management pro-
gram, including changes to diet, physical activity, and
behavior goal setting [9]. Supporting these guidelines, stu-
dies of lifestyle interventions indicate that the most suc-
cessful determinants are those that include an educational
component addressing diet and physical activity, as well as
behavior therapy, incentives, and health professional fol-
low-up [10]. It is also recommended that individualized
goals be set to reduce body weight at an optimal rate of
0.5 to 1 kg per week for the first 6 months to achieve an
overall 10% weight loss [9]. Behavioral counseling has
assisted overweight and obese patients to achieve clinically
significant (3-5 kg) weight loss that is sustainable for up to
2 years [1,9-11]. However, the treatments that have been
proven to work present a number of barriers including
cost, access, and large-scale implementation.
Barriers to Obesity Treatment
The current healthcare system cannot manage the large
numbers of patients who need weight loss treatment.
Evidence suggests that meaningful obesity treatment
must provide individuals with frequent and immediate
feedback about diet, exercise, and ways to implement
new behaviors in order to achieve weight loss [12]. The
costs for these types of treatment are far beyond what
individuals and the healthcare system can sustain [12].
U.S. obesity-attributable medical expenditures are esti-
mated at $75 billion annually, with $17 billion financed
by Medicare and $21 billion financed by Medicaid [13].
If the trend toward obesity continues, these expendi-
tures will reach up to 16-18% of total U.S. healthcare
costs by 2030, equaling $861-957 billion dollars [14].
The challenge for interventions dealing with obesity is
to identify how these treatments can be integrated into
everyday care in cost effective ways that are not burden-
some to patients.
Pain is also considered a barrier in healthy lifestyle
interventions, especially in the older population when
integrating an exercise component. In the general popu-
lation and among Veterans, elevated BMI is correlated
with reported pain [15,16]. Obesity co-occurs with a
number of chronic pain conditions including degenera-
tive arthritis, low back pain, and musculoskeletal pain
[17,18]. In combination, pain and obesity have an addi-
tive negative effect on health-related quality of life, a
finding demonstrated in both patients seeking treatment
for obesity[16] and patients seeking treatment for
chronic pain [19]. The impact on health care expendi-
tures is substantial because both obesity [20-22] and
pain [23,24] are associated with increased care utiliza-
tion. Healthy lifestyle change is therefore a shared focus
of empirically validated treatments for both obesity and
chronic pain. The proposed intervention was developed
to address the aforementioned barriers to obesity care
by delivering effective behavioral components while deli-
vering high intensity, low cost obesity treatment.
MOVE! Obesity Treatment
Large scale institutions such as Medicare, the National
Institutes of Health (NIH), the National Centers for
Prevention (NCP), and the Veterans Affairs Medical
Centers (VAMC) have all recognized the impact of the
obesity epidemic and have developed community-based
treatment interventions. One such development is the
nationally based Managing Obese Veterans Everywhere
(MOVE!) program offered at VA medical centers.
MOVE! is a response to the obesity crisis affecting the
veteran population at a significantly higher rate (73%
males and 68% females) than the general population
(67% males, 62% females) [25]. MOVE! is a stepped care
program for obesity treatment, using 5-level treatment
model. Level 1 implements self-assessment (MOVE! 23
questionnaire) and guided self-care. Level 2, targeted for
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their primary care physician or dieticians that they are
ready to make behavioral changes in diet and physical
activity. Patients receiving Level 2 treatment utilize the
Level 1 assessment and self-care strategies, but also par-
ticipate in group sessions and consultation addressing
nutrition, physical activity, and behavior change. MOVE!
Levels 3 - 5 involve pharmacological, inpatient, and sur-
gical treatments respectively. Levels 1-2 are the most
widely implemented delivery formats of MOVE!;h o w -
ever they present some practical barriers for those
requiring treatment. Veterans identify barriers to partici-
pation that includes the time of day the program is
offered, and an inability to travel to the hospitals where
the program is offered. One potential way to overcome
these obstacles is to introduce novel technology that
enables cheaper, distance participation and swifter
response times as part of obesity treatment.
Improving Obesity Treatment with Handheld Technology
Self-monitoring has emerged as a critical skill for obesity
management [26-28]. Those who report monitoring their
weight on a daily or weekly basis have greater success in
achieving weight loss goals [7,29-31]. Several studies have
shown that PDAs are a reliable tool for dietary self-moni-
toring and have improved compliance and health indicators
(i.e. dietary intake, glucose monitoring, blood pressure)
[12,32-34] In spite of these findings, research on the use of
handheld technology for self-monitoring behavior, and the
impact of integrating a PDA on weight loss into behavioral
weight control programs is limited [35]. Handheld technol-
ogy holds great promise as a mechanism for supporting
and disseminating behavioral interventions because
they can deliver tailored messages at the point of decision-
making in response to the needs of the user at that moment
[36,37].
The PDA platform we have developed automatically
codes dietary data, and has algorithms that immediately
provide real-time feedback about calorie consumption
and daily physical activity. Recording dietary intake and
activity onto a PDA can motivate timely reporting
namely because the user receives immediate feedback
relative to their goals. Our technology circumvents the
need for pencil and paper reports, which is cumbersome
because it requires patients to carry and record onto
forms, is prone to significant inaccuracies, and is not sub-
ject to timely feedback [26,38]. Another advantage to
using handheld technology is that the safety of distance
communication may enable patients to feel less self-
conscious and freer to report accurately and communi-
cate openly [12,26,33,38]. Installing decision-support
tools on the PDA reduces the costs associated with face-
to-face meetings with professionals and encourages the
regular practice necessary to maintain skill acquisition
over time. As a delivery vehicle, the PDA is convenient,
removes access barriers, allows tailoring, and dissemi-
nates knowledge and expertise in a manner that empow-
ers patients. Our study will implement a PDA that can be
integrated into existing care, which may substantially
increase the accessibility of an intervention while elimi-
nating the costs associated with intensive weight loss
treatment. What is particularly exciting about our study
is that we hope to develop a modularized treatment tool
that can be independently introduced to programs to
increase efficacy and decrease costs.
Study Aims
The primary aims of the proposed study are to determine
whether overweight and obese patients with chronic pain
who are randomized to the Standard Care + PDA group
(PDA+) show more weight loss over a 6-month period,
greater maintenance of weight loss at 12 months, and
greater reduction in pain intensity and pain-related dis-
ability than those randomized to receive Standard Care
only. We hypothesize that the addition of a PDA weight
loss decision-support tool for patients plus personalized
coaching will improve weight loss, weight loss mainte-
nance, and pain reduction for obese patients with chronic
pain, as compared to MOVE! standard care.
The secondary aims are to determine whether over-
weight/obese patients with chronic pain who are rando-
mized to the PDA+ group will show significantly
improved quality of life, greater treatment adherence,
and reduced care utilization as compared to Standard
Care only.
Secondary hypotheses are that the addition of a PDA
weight loss decision-support tool for patients plus per-
sonalized coaching will improve quality of life and treat-
ment adherence and will reduce health care utilization,
as compared to MOVE! standard care alone. Ancillary
outcomes that will be collected are patient satisfaction,
mood, and waist circumference.
Methods
Study Design
The research design is a 2 × 5 factorial involving one
between subject’s factor (treatment condition) with 2
levels (Standard Care vs. Standard Care+ PDA (PDA+)
and one within subject’s factor (time) with 5 levels (rando-
mization, 3-, 6-, 9-, and 12-month follow-up). Participants
will be followed through three trial phases (Figure 1).
Description of Study Technology
PDA Technology
Existing diet and activity monitoring technology on the
PDA platform is limited. No other available software
packages that we know of are theory based, persona-
lized, and can be integrated into pre-existing weight loss
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sufficient empirical support to adapt to a large scale
RCT as the one proposed. While the automaticity of
feedback is a component of existing technology [7,32],
the personalized nature of the daily feedback promises
to deliver a more potent intervention.
The PDA tool, a modified version of handheld technol-
ogy used in the Making Better Choices Study [39], is a
patient centered decision-support system that promotes
weight loss by helping participants to self-regulate eating
and physical activity behaviors. The food database (used
for the Nutritionist Pro Nutritional analysis program)
contains accurate, up-to-date food and nutrient data for
more than 18,000 foods, including brand-name foods,
fast foods, and ethnic foods. The PDA program we devel-
oped has a user-friendly interface that enables partici-
pants to enter food intake and activity information. By
converting complex dietary and activity data into two
simple energy intake and expenditure thermometers, the
PDA system will function as a decision support tool to
help people track and make decisions about their
momentary behaviors in relation to daily goals. Partici-
pants in the PDA+ group will also be oriented to the cus-
tomizable feedback “thermometers” visually depicting
how much of the day’s calorie allowance has been used
up and what proportion of the day’s physical activity goal
has been attained thus far.
Accelerometer Technology
Participants randomized to the PDA+ group will be given
an accelerometer (Biotrainer II, IM Systems, Baltimore,
MD) to be worn on the hip. This triaxial accelerometer
tracks moderate intensity activity by the number of
counts displayed, which will provide the study team and
participants with an accurate objective measure of physi-
cal activity achieved (http://www.imsystems.net/btpro/
btpro.htm). The Biotrainer II has been shown to
automatically detect changes in physical activity intensity,
which is much more accurate than self-report [40]. The
Biotrainer II will be individually calibrated for each parti-
cipant, by walking on a treadmill for five minutes to
demonstrate moderate intensity activity to the partici-
pant, and to orient the participant to the device display.
Participants in the PDA+ group will be instructed to
wear the accelerometer at all times except when
immersed in water or sleeping, and re-zero the display
reading at the end of each day after entry into the PDA.
Data Collection
Data will be collected at various time points beginning
at baseline and continuing through 12-month follow-up
on continuous and dichotomous variables using the
measures [41-50] in Table 1. Anthropomorphic mea-
sures of weight, height and waist circumference will be
collected at each in-person session. Participants in the
PDA+ group will remotely upload diet, physical activity,
pain and mood data to their coach weekly. Data from
the accelerometer will be collected at follow-up appoint-
ments. Participants will be paid $20 at randomization
and at each in-person follow-up session to create an
incentive that encourages retention (Total $100).
Recruitment and Screening Procedures
The study procedures are approved by the Institutional
Review Board at the Hines VA Medical Center. Partici-
pants who pass initial eligibility screening, will then
undergo a written informed consent process prior to
beginning the study protocol. To be eligible, veterans
must be enrolled in the MOVE! group at the Hines Hos-
pital VAMC with BMI ≥ 25 and ≤ 40 and weigh < 400
pounds, experience chronic pain ( ≥ 4o nt h eN R S - I
scale for ≥ 6 months prior to enrollment) and are able
to participate in a moderate intensity exercise program
will be recruited. The enrollment policy is consistent
with the 2005 VA/DoD Practice Guideline that recom-
mends obesity treatment for all Veterans with BMI ≥ 25
and consideration of supplemental pharmacotherapy
and surgical treatments for severely obese patients with
BMI ≥ 40 [51]. Further eligibility criteria is listed in
Table 2.
Training
All eligible participants will receive and be trained to
properly use the PDA to report dietary intake (that is
automatically time and date stamped), moderate inten-
sity physical activity minutes, and weight from a digital
scale to the coach. An exclusionary competency check is
administered to ensure that the participant can accu-
rately enter a sample meal, minutes of physical activity,
and their weight into the PDA. Once demonstrated, the
Figure 1 PDA+ Trial Phases.
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be scheduled for a randomization session in 7-14 days.
Baseline Period
Baseline is a two week period in which the participant
records food intake, weight, and activity into the PDA
and uploads data to the study server each night. During
the baseline period, participants will be required to meet
the following eligibility criteria: a) record ≥ 2 meals per
day and have ≥ 2 items per meal recorded, and b)
record their daily weight in the morning. Coaches will
provide corrective feedback when implausible reports
suggest inaccurate or untimely recording (i.e: only 500
calories consumed the entire day). During the baseline
phase, the intake and expenditure thermometers will
not be visible to the participants. Randomization will
occur if all eligibility criteria are met.
Randomization
Prior to randomization and to discourage heightened
attrition in the control group, a brief motivational inter-
viewing intervention will be performed to make salient
the pros and cons of being randomized to either condi-
tion. Participants will be re-assessed about their readi-
ness to make lifestyle changes by administering the
Exercise and Weight Stages of Change Short Forms [42]
to identify and exclude pre-contemplators.
Participants will be randomly assigned to one of two
g r o u p s :a )S t a n d a r dC a r eo rb )S t a n d a r dC a r e+ P D A
(PDA+). Group randomization will be computer-gener-
ated via the method of randomly permuted blocks.
The use of permuted blocks preserves balance in the
randomization over the course of the study, to main-
tain equal sample sizes in the two experimental condi-
tions. Randomization will be stratified by age (≤ 65 vs.
> 65), BMI (< 35 vs. ≥ 35), and gender, to maintain
e q u a ln u m b e r so fw o m e na n dm e ni ne a c ht r e a t m e n t
condition.
Once randomized, those in the standard care group
will no longer record their intake, weight, or activity
using the PDA. The group will return all study equip-
ment and attend MOVE! groups and follow-up lab ses-
sions as scheduled.
Since the proposed design is additive (i.e., it tests the
effects of adding technology and coaching to standard
care), it is important to establish that the standard care
received by participants is equivalent across conditions
(e.g., entails comparable intervention components and
level of interventionist expertise). To prevent contami-
nation, MOVE! group leaders will be different indivi-
duals than those who train and coach participants
randomized to the PDA conditions.
Table 1 Measures
Measures Baseline 3-month 6-month 9-months 12-months
Stage of Change
Exercise Stage of Change Short Form xxx x x
Weight Loss Stage of Change Short Form xxx x x
Readiness to Change Pain Question xxx x x
Pain Stage of Change Questionnaire (PSOCQ) xx x
Psychological Variables
PRIME-MD x
Breath Holding Task x
West Haven-Yale Multidimensional Pain Inventory (WHYMPI) xxx x x
Distress Tolerance Scale xxx x x
Numeric Scale of Pain Intensity (NRS-I) x
Quality of Life (SF-36) xxx x x
Positive and Negative Affect Schedule (PANAS) xxx x x
Other Variables
VHA Patient Satisfaction Survey xx
Computer Email Web Literacy (CEW) x
Table 2 Eligibility Criteria
Eligibility Criteria
￿ Willing to participate in a 12-month study
￿ Independently Mobile (no cane, walker, wheelchair needed)
￿ Can participate in regular exercise
￿ No psychiatric hospitalizations within the past year
￿ No cognitive or sensorimotor impairment
￿ Cannot participate in a structured diet program outside of study
￿ Cannot be at high risk for adverse CVD events while exercising
￿ Considering making changes to lose weight in the next 6 months
1
￿ Absence of any substance abuse, mood, or binge eating disorder that
would interfere with adherence
2
￿ Must experience chronic pain (≥ 4 on the NRS-I scale for ≥ 6 months
prior to enrollment)
1As measured by the Exercise and Weight Stages of Change Form.
2As measured by the PRIME-MD.
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Calorie and Weight Loss Goals
Patients randomized to the treatment group will continue
to upload their dietary data daily, as well as their mood,
pain level, and accelerometer data (Figure 2). Successful
completion of 7 days of PDA uploading meets the mas-
tery criterion for recording and uploading, and will trig-
ger activation of the PDA’s treatment protocol (Figure 3).
Rather than progressing through eating goals in a lock-
step manner at fixed time intervals, progress will be mas-
tery-based (triggered by accomplishment of each prior
goal), which will help to minimize frustration and failure
and reinforce intrinsic motivation.
Every two weeks for the next 6 months, coaches will
review participants’ data to evaluate if they have met
their weight loss, calorie, and behavioral goals. If, after
meeting their caloric goals, participants do not lose
weight for two consecutive weeks, they will be instructed
to reduce calories in 100 kcal increments until they reach
a calorie intake level that yields a weight loss rate of
.5-1% of their current weight per week. No patient will be
given an intake goal below 1200 kcal per day. Conversely,
if the rate of weight loss is too rapid (operationalized as
weight loss of ≥ 3 pounds/week for 4 consecutive weeks),
calorie intake goal will be increased in 100 kcal incre-
ments until attainment of the goal of .5-1% of current
weight is lost per week for two weeks is achieved.
Physical Activity Goals
Once participants have been provided with calorie
intake goals for four weeks, a physical activity goal will
be added. Coaches will assist participants in determining
the types of activities that are ideal, which are based on
interest, skill, and conditioning level. Physical activity
goals are calculated and assigned using algorithms that
set the treatment goals in a stepwise fashion, such that
forward progression is mastery-based (i.e., patient pro-
ceeds to next goal only after first goal has been met).
Maintenance Phase (months 7-12)
During the maintenance phase, the focus is to maintain
goals set during the weight loss phase of the study. Par-
ticipants are required to upload two weeks per month in
months 7-9, and one week per month in months 10-12.
The coach will monitor data uploads and remind parti-
cipants to record and upload data if it is not completed
during the pre-designated time points.
Data Analysis
Sample Size & Power Estimate
Sample size calculations were determined using a large VA
sample provided by National Center for Health Promotion
and Disease Prevention (NCP) to estimate weight loss
achieved by MOVE! participants during a 6-month period.
VA NCP data show that MOVE! patients who attended at
least one group visit showed a weight loss of 6.36 lbs (s.d.
= 11.68; N = 166) over 6 months [52]. Additionally, these
same subjects had a correlation of .977 between their base-
line and 6-month follow-up weight measurements.
Accordingly, we expect the Standard Care group’s weight
loss to be 6 lb (s.d. = 12) over 6 months, and we conserva-
tively assume this same weight loss level to be maintained
at 12 months. A clinically meaningful increment in weight
loss would occur if adding the PDA decision support tool
produced a 12 lb. weight loss. Thus, we posit a 6 lb differ-
ence between our control and intervention groups.
To calculate power in terms of a comparison of weight
measurements over time, we used methods described in
Hedeker et al [53]. For this, we assume that there will be
75 participants per group at baseline, and an attrition rate
of 4% at each measurement wave (i.e., an overall retention
rate of 85% at 12-months). We also conservatively assume,
based on the aforementioned VA study, that the correla-
tion of the repeated weight measurements equals .95.
Given these assumptions, power is in excess of .80 for a
two-tailed .05 hypothesis test for the standard care versus
PDA+ group contrast comparing baseline weight versus
weight at all follow-up measurements (i.e., 3-, 6-, 9-, and
12-month follow-ups) under the following scenario: a 0 lb
group difference at baseline and a 6 lb group difference at
all subsequent timepoints (i.e., an effect size of 6/50 = .12
at these four follow-up timepoints).
For comparing weight at specific timepoints, we con-
sidered power in terms of weight change at the final
timepoint, since it is at that timepoint that the sample
is smallest. At 12 months, we expect there to be 75 ×
.85 = 64 subjects per group. If we again assume a clini-
cally meaningful difference of 6 pounds, and given the
Figure 2 Screen shot of the goal thermometers.T h eg o a l
thermometers reflect the calories and moderate activity of a
hypothetical participant.
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VA study, we are interested in an effect size of .5 SD
units. For this, power is in excess of .80 for a two-
tailed .05 hypothesis test for this comparison at the
final timepoint.
Analysis
Outcomes will be analyzed longitudinally on an intent-
to-treat basis. Our general analytic approach will be
to use longitudinal mixed-effects regression models
(MRMs) implemented via SAS PROC MIXED. A priori
Randomization 
Standard Care 
MOVE! Group attendance 
Standard Care + PDA (PDA+) 
MOVE! Group attendance 
Recording diet, mood, physical activity, and pain level into PDA 
Behavioral Weight Loss Coaching 
One week mastery period 
Activation of behavioral change algorithm 
Biweekly Coaching Sessions 
Calorie goal assigned based on starting weight* 
.5-1% weekly weight loss target assigned
+ 
Behavioral strategies for weight loss discussed with coach 
Physical Activity Goal assigned one month after randomization
- 
3-Month Follow-Up Session 
Anthropomorphic measurements collected 
Report Medication Changes 
Assessment Battery Administered 
5-minute Treadmill Moderate Activity Exercise (PDA+ group only) 
Biweekly Coaching Sessions Continue 
 
6-Month Follow-Up Session 
Anthropomorphic measurements collected 
Report Medication Changes 
Assessment Battery Administered 
5-minute Treadmill Moderate Activity Exercise (PDA+ group only) 
Month 7: Maintenance Phase Begins 
Bi-Weekly Coaching Discontinues 
Record Data biweekly 
9-Month Follow-Up Session 
Anthropomorphic measurements collected 
Report Medication Changes 
Assessment Battery Administered 
5-minute Treadmill Moderate Activity Exercise (PDA+ group only) 
Month 10: Maintenance Phase Continues 
Record Data Once Monthly 
12-Month Final Follow-Up Session 
Anthropomorphic measurements collected 
Report Medication Changes 
Assessment Battery Administered 
5-minute Treadmill Moderate Activity Exercise (PDA+ group only) 
* Participants that weigh > 250 lbs., start at 1800-1500 kcalories (kcal), Those who weigh < 250, will start between 1500-1200 kcal. 
+ Participants will also be given a weekly weight loss target, which is equal to .5-1% of their current weight.   
- Participants who have not recorded physical activity will start at a 15 minute/day goal. The goal in minutes will be increased by 25% incrementally until 60 minutes per day is achieved 
 
Figure 3 Protocol Timeline. Participant progression through the study protocol.
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Page 7 of 10contrasts will be estimated for the standard care versus
PDA+ comparison. We will also include all stratification
variables (age, BMI, gender) in all analyses.
Following the guidelines of Fitzmaurice and colleagues
(2004) we will model weight (in lbs) at all timepoints
(baseline, 3-, 6-, 9, and 12-months) including both linear
and quadratic effects of time (to allow for curvilinearity
in weight across time), and group by time interactions
[54]. As these authors recommend, we will include base-
line weight as part of the dependent variable vector, and
further assume that the group means are equal at base-
line. This approach yields a valid estimate of treatment
group comparisons that is generally more powerful than
other alternatives. Our primary tests will be for the pre-
sence of the group by time interaction terms, which will
indicate the degree to which group differences in weight
are present after baseline, and the degree to which any
group differences are maintained over time
Though MRMs permit missing data across time, they
do assume that the missing data are missing at random
(MAR). MAR allows the missingness to be related to
covariates (i.e., time, group, initial BMI) and also
observed values of the dependent variable across time
(i.e., a subject’s observed weight measurements). Since
many experts advise that MAR analysis is reasonable for
most longitudinal clinical trials, we will use our MRM
analysis as the primary approach [54,55]. However, we
will also conduct sensitivity analyses to examine how
robust our results are to missing data aspects using
models that go beyond MAR. Specifically, we will addi-
tionally estimate pattern-mixture models [56] and
shared parameter or selection models [57] to give us a
sense if our conclusions vary at all by assumptions
regarding the missing data.
Discussion
The proposed research is significant in that it will test a
cutting edge intervention to treat obesity. For the VA,
the intervention described interfaces with existing
MOVE! obesity programming, but aims to extend its
reach and effectiveness. In addition to addressing obe-
sity, the intervention secondarily targets pain, thus
addressing two prevalent and significant clinical condi-
tions for the VA. The research seeks to improve Veter-
ans’ quality of life by using innovative health technology
in the form of a promising, non-invasive treatment that
can be employed quickly and in a cost-effective manner
throughout the VA system. This intervention is particu-
larly cutting edge because it will investigate technology
use in an older, predominantly male sample. Interven-
tions such as this one will advance the understanding of
older male weight loss patterns, as well as the develop-
ment of effective programming to decrease the risk for
obesity related comorbidities.
Technology based interventions offer scalable mechan-
ism that may increase the scope and effectiveness of obe-
sity treatment. Evidence suggests that technology based
interventions produce better weight loss results
[7,12,27,29,32,58], and increased adherence during the
course of treatment [12,26,32,35]. The treatment pro-
vided in this study will build upon the strengths of tech-
nology based intervention as well as examine emerging
technologies that make weight loss programs more acces-
sible to a wide range of patients who may be less techno-
logically savvy. The strength of this intervention is that it
will integrate self-monitoring, timely feedback, regular
weight monitoring, nutrition education, and behavioral
weight loss strategies–all components of successful
weight loss treatments.
The design of PDA+ will allow us to evaluate several
hypotheses. We predict that the addition of a weight-loss
decision support tool plus personalized coaching will
result in greater weight loss at 6- and 12- months, as well
as greater maintenance at 12-months. We also predict
that the weight loss outcome will in turn affect subjective
measures of pain, thus increasing quality of life out-
comes. What is unclear is how these tools are dissemi-
nated into the health care system, as well as if outcomes
are affected as significantly when implemented at as part
of a pre-existing weight loss program.
The limitations of the generalizability of the study
results warrant consideration. The population in which
the intervention is being studied may not be representa-
tive of the population-at-large. Veterans have access to
the MOVE! Group, which is a highly specialized pro-
gram, and is not offered to all health care consumers.
Another consideration is that the older population may
have increased motivation to lose weight due to a higher
incidence of health problems that would benefit from
weight loss, as well as increased time per day to record
into the palm program. However, given the obesity epi-
demic rates in the general population, the incidence of
comorbid conditions will likely motivate increased
weight loss efforts globally. The technology as a whole is
expensive, and may not be accessible to all populations
or reimbursable or accepted by public consumers.
Further research is needed to specify the components of
an intervention that can be scaled down to make the
intervention more cost-effective. Design considerations
must also be warranted in that the control group will
have baseline exposure to the PDA device. The exposure
may lead our control group to differ from those who
have no exposure to the technology.
In sum, the PDA+ study represents an important step
in understanding how to improve the use of technology
in obesity treatment. The trial will answer the questions
of how to provide lower-cost, effective, and efficient
treatment, something that the VA continues to identify
Duncan et al. BMC Public Health 2011, 11:223
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Page 8 of 10as an important component of providing care to a large
number of patients. Considering that the obesity epi-
demic is not losing momentum, this suggests the impor-
tance of this trial that tests improved strategies to treat
overweight and obese patients.
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